Andrew Adams has served as an advisor to the Sema4 Board of Directors since August 2019.
Currently, Andrew is also a Co-Founder and Managing Partner of Oak HC/FT where he focuses on growth equity and early-stage venture opportunities in Healthcare.
In addition to being a Board Observer at Sema4, Andrew serves on the Boards of August Bioservices, DispatchHealth, Galileo, Paladina Health, Therapy Brands, US HealthVest and WithMe Health. Andrew is also actively involved with Independent Living Systems, One Medical Group and Precision Medicine Group.
Prior investments include American Esoteric Laboratories (acquired by Sonic Healthcare Limited), Argus Information & Advisory Services (acquired by Verisk Analytics), Benefitfocus (NASDAQ: BNFT), CareMedic Systems (acquired by Ingenix), CLARiENT (acquired by GE Healthcare), Core Informatics (acquired by Thermo Fischer Scientific), Health Dialog (acquired by British United Provident Association), iHealth Technologies (merged with Connolly), LDI (acquired by Diplomat Pharmacy), Limeade (ASX: LME), Maestro Health (acquired by AXA Group), NetSpend Corporation (acquired by TSYS), PayFlex Systems (acquired by Aetna), PharMEDium Healthcare (acquired by CD&R), United BioSource (acquired by Medco Health Solutions) and One Medical Group (NASDAQ: ONEM).
Andrew also serves as a General Partner of Oak Investment Partners which he joined in 2003. Prior to joining Oak Investment Partners, Andrew was a Senior Associate with Capital Resource Partners, a mezzanine capital firm where he focused on investments in healthcare and business services companies. Andrew was also a Financial Analyst in the media and communications group of Deutsche Banc Alex. Brown.
Andrew received his B.A. degree from Princeton University.
Any small, remote beach
Spend time with family
“Shoe Dog: A Memoir by the Creator of Nike” by Phil Knight